HealthCare atHOME India (“HCAH”) today announced its plans to launch a unique internet based healthcare service in India in partnership with Japan’s prestigious $10 billion healthcare media company M3, Inc. (“M3”).
Through this partnership, HCAH, and M3 will provide Indian Doctors an on-line, and mobile platform to stay connected to news, best practices, innovations, and the latest research from global peers, and experts. The digital platform, aimed at the healthcare community, will also offer customized, and continued medical education(CME) that will help improve practices, and also improve patient care in the long-term.
The company will work closely with other key players in the healthcare sector including Pharma companies, Healthcare service providers [hospitals], and the Government to improve the quality of communication, and dissemination of relevant medical information amongst various stakeholders in the healthcare fraternity.
M3 is listed on the Tokyo stock exchange with over US$10 billion in market capitalization, and offers a wide range of value add services to pharmaceutical companies, and hospital clients globally. The company will introduce several of these services to the Indian market.
HCAH, and M3 expect the growth of the market for digital marketing of pharmaceutical products to exceed 24 billion rupees ($360 million) by 2020. M3 has a successful track record in Japan, U.S., Korea, U.K., and China. With this partnership, M3 will now directly cover countries inhabited by roughly 3.3 billion people or 40% of the world’s population.
Commenting on this new partnership, Mr. Gaurav Burman, Founder and Director of HCAH said “I have believed from the moment I learnt about M3’s operations that its revolutionary and unique approach to building a digital network to connect the Global Healthcare Community would be hugely beneficial to the Indian Healthcare market. I am delighted that we have been able to launch this partnership, and believe that the business will be extremely successful”
Mr. Vivek Srivastava, Co-Founder and CEO of HCAH said “This JV will help HCAH increase its service offerings to the healthcare & life sciences sector. Our Pharma clients will be able to reduce their costs, and increase the reach of their drugs. With the high value content we will be able to offer doctors, and practitioners, we hope it will give them an opportunity to broaden their knowledge and network. This will improve clinical outcomes and costs for the patients over the long term.”
Speaking about the collaboration, Mr. ItaruTanimura, Representative Director of M3, stated “We are pleased to collaborate with HCAH which we view as the leading home health care provider in India. We expect to leverage the strengths of HCAH, and the Burman family’s trusted brand, and deep networks within the healthcare, and pharmaceutical industries. This will be an exciting journey”.
M3 operates and has affiliations with web portals for medical professionals spanning across 24 countries globally in partnership with HCAH wewill further strengthen the network of medical professionals across the world.
Through this partnership, HCAH, and M3 will provide Indian Doctors an on-line, and mobile platform to stay connected to news, best practices, innovations, and the latest research from global peers, and experts. The digital platform, aimed at the healthcare community, will also offer customized, and continued medical education(CME) that will help improve practices, and also improve patient care in the long-term.
The company will work closely with other key players in the healthcare sector including Pharma companies, Healthcare service providers [hospitals], and the Government to improve the quality of communication, and dissemination of relevant medical information amongst various stakeholders in the healthcare fraternity.
M3 is listed on the Tokyo stock exchange with over US$10 billion in market capitalization, and offers a wide range of value add services to pharmaceutical companies, and hospital clients globally. The company will introduce several of these services to the Indian market.
HCAH, and M3 expect the growth of the market for digital marketing of pharmaceutical products to exceed 24 billion rupees ($360 million) by 2020. M3 has a successful track record in Japan, U.S., Korea, U.K., and China. With this partnership, M3 will now directly cover countries inhabited by roughly 3.3 billion people or 40% of the world’s population.
Commenting on this new partnership, Mr. Gaurav Burman, Founder and Director of HCAH said “I have believed from the moment I learnt about M3’s operations that its revolutionary and unique approach to building a digital network to connect the Global Healthcare Community would be hugely beneficial to the Indian Healthcare market. I am delighted that we have been able to launch this partnership, and believe that the business will be extremely successful”
Mr. Vivek Srivastava, Co-Founder and CEO of HCAH said “This JV will help HCAH increase its service offerings to the healthcare & life sciences sector. Our Pharma clients will be able to reduce their costs, and increase the reach of their drugs. With the high value content we will be able to offer doctors, and practitioners, we hope it will give them an opportunity to broaden their knowledge and network. This will improve clinical outcomes and costs for the patients over the long term.”
Speaking about the collaboration, Mr. ItaruTanimura, Representative Director of M3, stated “We are pleased to collaborate with HCAH which we view as the leading home health care provider in India. We expect to leverage the strengths of HCAH, and the Burman family’s trusted brand, and deep networks within the healthcare, and pharmaceutical industries. This will be an exciting journey”.
M3 operates and has affiliations with web portals for medical professionals spanning across 24 countries globally in partnership with HCAH wewill further strengthen the network of medical professionals across the world.
Advertisements